TABLE 1.
Characteristics of the Included Studiesa
| Sample Size | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Lead Author (Year) | PRP | Control | PRP Type | Spinning Approach | Activator | No. of Injections | Control Group | Outcome Measure | Follow-up, mo |
| Cerza (2012)5 | 60 | 60 | LP | Single | NR | 4 | HA | WOMAC Pain subscale | 6 |
| Sánchez (2012)38 | 89 | 87 | LP | Single | CaCl2 | 3 | HA | WOMAC Pain and Function subscales, adverse events | 6 |
| Patel (2013)32 | 27 | 23 | LP | Single | CaCl2 | 1 | Saline | VAS | 6 |
| Vaquerizo (2013)44 | 48 | 48 | LP | Single | CaCl2 | 3 | HA | WOMAC Pain and Function subscales, adverse events | 6, 12 |
| Raeissadat (2015)34 | 77 | 62 | LR | Double | No | 3 | HA | WOMAC Pain and Function subscales | 12 |
| Forogh (2016)14 | 24 | 24 | LR | Double | CaCl2 | 1 | CS | VAS | 6 |
| Lana (2016)24 | 36 | 36 | LR | Double | Thrombin | 3 | HA | WOMAC Pain and Function subscales, VAS, adverse events | 6, 12 |
| Smith (2016)40 | 15 | 15 | LP | Single | NR | 3 | Saline | WOMAC Pain and Function subscales, adverse events | 6, 12 |
| Cole (2017)7 | 49 | 50 | LP | Single | NR | 3 | HA | WOMAC Pain subscale | 6,12 |
| Duymus (2017)11 | 33 | 34 | LR | Single | No | 2 | HA | WOMAC Pain and Function subscales, VAS | 6, 12 |
| Joshi Jubert (2017)20 | 35 | 30 | LP | Double | No | 1 | CS | VAS, adverse events | 6 |
| Raeissadat (2017)35 | 36 | 33 | LR | Double | CaCl2 | 2 | HA | WOMAC Pain and Function subscales, VAS | 6 |
| Ahmad (2018)1 | 45 | 44 | LR | Single | NR | 3 | HA | VAS, adverse events | 6 |
| Buendía-López (2018)4 | 33 | 32 | LP | Double | CaCl2 | 1 | HA | WOMAC Pain and Physical Function subscales, VAS, adverse events | 6, 12 |
| Uslu Guvendi (2018)43 | 19 | 17 | LR | Single | NR | 3 | CS | WOMAC Pain and Function subscales | 6 |
| Louis (2018)26 | 24 | 24 | LR | Double | CaCl2 | 1 | HA | WOMAC Pain and Function subscales, VAS, adverse events | 6 |
| Nabi (2018)31 | 33 | 34 | LR | Double | NR | 3 | CS | VAS, adverse events | 6 |
| Su (2018)42 | 25 | 30 | LR | Double | CaCl2 | 2 | HA | WOMAC Pain and Function subscales, VAS, adverse events | 6, 12, 18 |
| Wu (2018)45 | 20 | 20 | LR | Single | NR | 1 | Saline | WOMAC Pain and Function subscales, adverse events | 6 |
| Yu (2018)48 | 104 | 88 | LR | NR | NR | 1 | HA | WOMAC Pain and Function subscales, adverse events | 12 |
| Huang (2019)17 | 40 | 40 (HA); 40 (CS) | LP | Single | No | 3 | HA; CS | VAS, adverse events | 12 |
aCS, corticosteroid; HA, hyaluronic acid; LP, leukocyte poor; LR, leucocyte rich; NR, not reported; PRP, platelet-rich plasma; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.